dc.contributor.author |
Algara, Manuel |
dc.contributor.author |
Arenas, M. |
dc.contributor.author |
Marin, J. |
dc.contributor.author |
Vallverdu, I. |
dc.contributor.author |
Fernández-Letón, P.. |
dc.contributor.author |
Villar, J. |
dc.contributor.author |
Fabrer, G. |
dc.contributor.author |
Rubio, C. |
dc.contributor.author |
Montero, Ángel |
dc.date |
2020 |
dc.identifier |
https://ddd.uab.cat/record/227835 |
dc.identifier |
urn:10.1016/j.ctro.2020.06.005 |
dc.identifier |
urn:oai:ddd.uab.cat:227835 |
dc.identifier |
urn:pmid:32613089 |
dc.identifier |
urn:pmcid:PMC7317159 |
dc.identifier |
urn:pmc-uid:7317159 |
dc.identifier |
urn:articleid:24056308v24p29 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:7317159 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Clinical and Translational Radiation Oncology ; Vol. 24 (june 2020), p. 29-33 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
dc.rights |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.subject |
COVID |
dc.subject |
Radiotherapy |
dc.subject |
Pneumonia |
dc.title |
Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19 : A proposal for a multi-centric prospective trial |
dc.type |
Article |
dc.description.abstract |
COVID-19 is a highly contagious viral infection with high morbidity that is draining health resources. The biggest complication is pneumonia, which has a serious inflammatory component, with no standardized treatment. Low-dose radiation therapy (LD-RT) is non-invasive and has anti-inflammatory effects that can interfere with the inflammatory cascade, thus reducing the severity of associated cytokine release and might be useful in the treatment of respiratory complications caused by COVID-19. This multicentric prospective clinical trial seeks to evaluate the efficacy of bilateral lung LD-RT therapy as a treatment for interstitial pneumonia in patients with COVID-19 for improving respiratory function. This prospective study will have 2 phases: I) an exploratory phase enrolling 10 patients, which will assess the feasibility and efficacy of low-dose lung irradiation, evaluated according to an increase in the PaO2/FiO2 ratio of at least 20% at 48-72 h with respect to the pre-irradiation value. If a minimum efficiency of 30% of the patients is not achieved, the study will not be continued. II) Non-randomized comparative phase in two groups: a control group, which will only receive pharmacological treatment, and an experimental arm with pharmacological treatment and LD-RT. It will include 96 patients, the allocation will be 1: 2, that is, 32 in the control arm and 64 in the experimental arm. The primary end-point will be the efficacy of LD-RT in patients with COVID-19 pneumonia according to an improvement in PaO2/FiO2. Secondary objectives will include the safety of bilateral lung LD-RT, an improvement in the radiology image, overall mortality rates at 15 and 30 days after irradiation and characterizing anti-inflammatory mechanisms of LD-RT by measuring the level of expression of adhesion molecules, anti-inflammatory cytokines and oxidative stress mediators. Trial registration: ClinicalTrial.gov NCT-04380818 . |